Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Exploring inflammasome activation and targeted inhibition

Descrizione del progetto

Approfondimento meccanicistico sulla difesa antinfiammatoria

In caso di infezione o danno cellulare, la cellula forma complessi citosolici noti come inflammasomi. Questi comprendono i recettori che rilevano specifici schemi molecolari correlati a patogeni o a rischi e il loro ruolo è quello di attivare le risposte infiammatorie favorendo la maturazione e la secrezione di citochine pro-infiammatorie. Finanziato dal Consiglio europeo della ricerca, il progetto NalpACT intende studiare il recettore dell’inflammasoma NLRP3 insieme ai principi fondamentali relativi al meccanismo di attivazione e inibizione del recettore. Inoltre, il lavoro si concentrerà sul ruolo di NLRP3 nella malattia di Alzheimer, aprendo la strada allo sviluppo di farmaci mirati.

Obiettivo

Inflammasomes are cytosolic multi-protein complexes that form in response to a wide range of pathogens, tissue damage, and other harmful stimuli. Members of the family of NOD-like receptors (NLRs) sense these pathogen and danger associated molecular patterns, triggering innate immune responses. NLRP3 is a well-studied NLR whose activation by a broad spectrum of stimuli leads to inflammasome formation and pyroptosis. Yet, the mechanisms inducing NLRP3 activation and the way how antagonistic small molecules counteract its function remain poorly understood. Just recently, we have determined the cryo-electron microscopy structures of full-length human NLRP3 in its inactive form and bound to the inhibitor CRID3. Native NLRP3 is a decamer composed of homodimers of intertwined LRR domains that assemble back-to-back as pentamers. We made the surprising finding that the effector pyrin domain is shielded inside the decamer cage providing a safeguard mechanism against accidental activation. To obtain insights into the activation mechanism of NLRP3 and the molecular formation of the inflammasome, I here propose a challenging and pioneering endeavour: employing biochemical, biophysical and structural analyses, we will resolve the structure of activated NLRP3 associated to lipid membranes, unravel its regulation by post-translational modifications, design specific inhibitors for the targeted protein degradation, and explore filamentous seeds for the maturation of Caspase-1 and Alzheimer’s disease forming amyloid-beta fibrils. Further, transferring our knowledge of CRID3-mediated NLRP3 inhibition to other NLRs as NLRP12 and NLRP1 will shed light on their mechanism of action and open new avenues for directed targeting. Collectively, this work will uncover fundamental molecular principles of inflammasome activation and the mode of action of anti-inflammatory drugs. I foresee, that these insights will open a wide field for the development of NLR-specific inhibitors as new medicines.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2022-ADG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

UNIVERSITATSKLINIKUM BONN
Contributo netto dell'UE
€ 2 155 047,00
Indirizzo
VENUSBERG-CAMPUS 1
53127 Bonn
Germania
Regione
Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 2 155 047,00

Beneficiari (1)